Download PDF
Aktuelle Rheumatologie 2009; 34(4): 220-225
DOI: 10.1055/s-0029-1220678
Übersichtsarbeit

© Georg Thieme Verlag KG Stuttgart · New York

„Switch” nach TNF-alpha-Hemmer Versagen: Eine adäquate Strategie?

Switch after Anti-TNF-alpha Failure: Is it an Adequate Strategy?M. Pierer1 , U. Wagner1 , O. Malysheva2 , C. Baerwald3
  • 1Universitätsklinikum, Sektion Rheumatologie/Gerontologie, Leipzig
  • 2Universitätklinikum Leipzig, Rheumatologie, Leipzig
  • 3University Hospital, Rheumatology Unit, Leipzig
Further Information

Publication History

Publication Date:
15 April 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Gegen Tumor-Nekrose-Faktor-Alpha (TNF-α) gerichtete Therapien haben die Behandlung der rheumatoiden Arthritis (RA) deutlich bereichert. Ein klinisches Problem ist derzeit, dass etwa ein Drittel der Patienten während einer Therapie mit einem TNF-α-Blocker keine messbare Symptombesserung erreicht. Weitere Probleme, die eine Therapieumstellung erfordern können, sind eine fehlende anhaltende Symptombesserung oder unerwünschte Wirkungen. Derzeit gibt es noch keine Leitlinien wie Patienten in dieser Situa-tion weiter behandelt werden sollten. Für einen Therapiewechsel gibt es mittlerweile mehrere gute Optionen, wobei sich in klinischen Studien und Kohorten zum Teil als praktikabel erwiesen hat, eine Umstellung („Switch”) auf einen zweiten TNF-α-Blocker vorzunehmen. Wie Studien und Kohorten zeigen, müssen jedoch Subgruppen von RA-Patienten definiert werden, die von einem Switch klinisch nicht profitieren. Das Konzept steht derzeit auf dem Prüfstand, zumal mit dem CD20-Antikörper Rituximab und dem T-Zell-Co-Stimulationsmodulator Abatacept alternative Therapiestrategien nach TNF-α-Blocker Versagen erhältlich sind. In dem Artikel beschreiben wir den Status quo der Studien zur Switch Situation und geben einen Ausblick auf mögliche Therapieoptionen.

Abstract

Therapies directed against tumour necrosis factor α (TNF-α) have revolutionised the management of patients with rheumatoid arthritis. However, it remains a clinical problem that approximately one-third of the patients do not respond adequately. Furthermore, it has become apparent that some patients gradually lose the effect over time or experience adverse effects with the TNFα antagonists. There are no clear guidelines on the therapy for these challenging patients. It might be useful to switch to another TNF-α antagonist that is supported by small studies and registries. However, cohort studies underline the necessity to identify patients who do not respond to such an anti-TNF switch. This is of particular interest since the T-cell co-stimulation antagonist Abatacept, as well as the B-cell depleting agent Rituximab, are also available for use in patients who have had an inadequate response or intolerance to the TNF-α antagonists. In this article, we review the current data and give an outlook on possible therapeutic strategies.

Schlüsselwörter

rheumatoide Arthritis - anti-TNF Therapie - abatacept - rituximab - switch

Key words

rheumatoid arthritis - anti-TNF therapy - abatacept - rituximab - switch

Literatur

  • 1  . Guidelines for the management of rheumatoid arthritis: 2002 Update.  Arthritis Rheum. 2002;  46 ((2)) 328-346
    CrossrefPubMedGoogle Scholar
  • 2 Alten R. Die Kostimulationsmodulation mit Abatacept: ein neuartiges und erfolgreiches Therapieprinzip in der Therapie der rheumatoiden Arthritis.  Akt Rheumatol. 2007;  32 271-277
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Bennett AN, Peterson P, Zain A. et al . Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.  Rheumatology (Oxford). 2005;  44 ((8)) 1026-1031
    CrossrefPubMedGoogle Scholar
  • 4 Blom M, Kievit W, den Broeder A. et al . Comparison of the Effectiveness of Rituximab and a Third TNF Blocking Agent after Failure of Two TNF Blocking Agents in Daily Clinical Practice.  ACR Presentation. 2008;  370 , Abstract
    PubMedGoogle Scholar
  • 5 Bombardieri S, McKenna F, Drosos AA. et al . Efficacy and safety of Adalimumab in 899 patients with rheumatoid arthritis (RA) who previously failed Etanercept and/or Infliximab in clinical practice.  Annals of the Rheumatic Diseases. 2006;  65 ((Suppl 2)) 178-17a , 1-6-2006. Abstract
    CrossrefPubMedGoogle Scholar
  • 6 Buch MH, Bingham SJ, Bejarano V. et al . Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.  Arthritis Rheum. 2007;  57 ((3)) 448-453
    CrossrefPubMedGoogle Scholar
  • 7 Buch MH, Seto Y, Bingham SJ. et al . C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.  Arthritis Rheum. 2005;  52 ((1)) 42-48
    CrossrefPubMedGoogle Scholar
  • 8 Cohen G, Courvoisier N, Cohen JD. et al . The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.  Clin Exp Rheumatol. 2005;  23 ((6)) 795-800
    PubMedGoogle Scholar
  • 9 Cohen SB, Emery P, Greenwald MW. et al . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.  Arthritis Rheum. 2006;  54 ((9)) 2793-2806
    CrossrefPubMedGoogle Scholar
  • 10 Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.  Curr Opin Rheumatol. 2002;  14 ((3)) 204-211
    CrossrefPubMedGoogle Scholar
  • 11 Di Poi E, Perin A, Morassi MP. et al . Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab.  Clin Exp Rheumatol. 2007;  25 ((1)) 85-87
    PubMedGoogle Scholar
  • 12 Emery P, Breedveld FC, Hall S. et al . Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.  Lancet. 2008;  372 ((9636)) 375-382
    CrossrefPubMedGoogle Scholar
  • 13 Emery P, Keystone E, Tony HP. et al . IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.  Ann Rheum Dis. 2008;  67 ((11)) 1516-1523
    CrossrefPubMedGoogle Scholar
  • 14 Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.  Joint Bone Spine. 2002;  69 ((1)) 12-18
    CrossrefPubMedGoogle Scholar
  • 15 Finckh A, Ciurea A, Brulhart L. et al . B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.  Arthritis Rheum. 2007;  56 ((5)) 1417-1423
    CrossrefPubMedGoogle Scholar
  • 16 Finckh A, Ciurea A, Kyburz D. et al . Rituximab in rheumatoid arthritis: duration of treatment response ans predictors of retreatrment in a population-based cohort.  Annals of the Rheumatic Diseases. 2007;  66 ((Suppl 2)) 123-12b , 1-6-2007. Abstract
    PubMedGoogle Scholar
  • 17 Finckh A, Simard JF, Duryea J. et al . The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.  Arthritis Rheum. 2006;  54 ((1)) 54-59
    CrossrefPubMedGoogle Scholar
  • 18 Furst DE, Gaylis N, Bray V. et al . Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.  Ann Rheum Dis. 2007;  66 ((7)) 893-899
    CrossrefPubMedGoogle Scholar
  • 19 Geborek P, Crnkic M, Petersson IF. et al . Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme in southern Sweden.  Ann Rheum Dis. 2002;  61 ((9)) 793-798
    CrossrefPubMedGoogle Scholar
  • 20 Genant HK, Peterfy CG, Westhovens R. et al . Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial.  Ann Rheum Dis. 2008;  67 ((8)) 1084-1089
    CrossrefPubMedGoogle Scholar
  • 21 Genovese MC, Becker JC, Schiff M. et al . Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.  N Engl J Med. 2005;  353 ((11)) 1114-1123
    CrossrefPubMedGoogle Scholar
  • 22 Genovese MC, McKay JD, Nasonov EL. et al . Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.  Arthritis Rheum. 2008;  58 ((10)) 2968-2980
    CrossrefPubMedGoogle Scholar
  • 23 Greenberg J, Gibofsky A, Reed G. et al . Effectiveness of TNF Inhibitors (TNF-I) in Biologic Naïve and Switched RA Patients in a U.  S. Cohort. ACR Presentation. 971;  2008 Abstract
    PubMedGoogle Scholar
  • 24 Hjardem E, Ostergaard M, Podenphant J. et al . Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?.  Ann Rheum Dis. 2007;  66 ((9)) 1184-1189
    CrossrefPubMedGoogle Scholar
  • 25 Hyrich KL, Lunt M, Watson KD. et al . Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.  Arthritis Rheum. 2007;  56 ((1)) 13-20
    CrossrefPubMedGoogle Scholar
  • 26 Hyrich KL, Symmons DP, Watson KD. et al . Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.  Arthritis Rheum. 2006;  54 ((6)) 1786-1794
    CrossrefPubMedGoogle Scholar
  • 27 Keystone EC, Emery P, Peterfy CG. et al . Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies.  Ann Rheum Dis. 2008;  68 ((2)) 216-221
    PubMedGoogle Scholar
  • 28 Klareskog L, van der HD, de Jager JP. et al . Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.  Lancet. 2004;  363 ((9410)) 675-681
    CrossrefPubMedGoogle Scholar
  • 29 Kremer JM, Genant HK, Moreland LW. et al . Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate.  Arthritis Rheum. 2008;  58 ((4)) 953-963
    CrossrefPubMedGoogle Scholar
  • 30 Kristensen LE, Christensen R, Bliddal H. et al . The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.  Scand J Rheumatol. 2007;  36 ((6)) 411-417
    CrossrefPubMedGoogle Scholar
  • 31 Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.  Arthritis Rheum. 2006;  54 ((2)) 600-606
    CrossrefPubMedGoogle Scholar
  • 32 Kruger K, Gaubitz M. Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis.  Z Rheumatol. 2008;  67 ((7)) 614-616
    CrossrefPubMedGoogle Scholar
  • 33 Lipsky PE, van der Heijde DM, St Clair EW. et al . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.  N Engl J Med. 2000;  343 ((22)) 1594-1602
    CrossrefPubMedGoogle Scholar
  • 34 Listing J, Strangfeld A, Rau R. et al . Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register.  Arthritis Res Ther. 2006;  8 ((3)) R66
    CrossrefPubMedGoogle Scholar
  • 35 Lutt JR, Deodhar A. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.  Drugs. 2008;  68 ((5)) 591-606
    CrossrefPubMedGoogle Scholar
  • 36 Maini R, St Clair EW, Breedveld F. et al . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.  ATTRACT Study Group. Lancet. 1999;  354 ((9194)) 1932-1939
    CrossrefPubMedGoogle Scholar
  • 37 Mancarella L, Bobbio-Pallavicini F, Ceccarelli F. et al . Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.  J Rheumatol. 2007;  34 ((8)) 1670-1673
    PubMedGoogle Scholar
  • 38 Manger B, Lorenz HM, Grünke M. et al . Zukünftiger Einsatz von Wirkstoffen gegen TNF-Alpha.  Akt Rheumatol. 2000;  25 75-78
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Moreland LW, Schiff MH, Baumgartner SW. et al . Etanercept therapy in rheumatoid arthritis.  A randomized, controlled trial. Ann Intern Med. 1999;  130 ((6)) 478-486
    CrossrefPubMedGoogle Scholar
  • 40 Nishimoto N, Hashimoto J, Miyasaka N. et al . Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.  Ann Rheum Dis. 2007;  66 ((9)) 1162-1167
    CrossrefPubMedGoogle Scholar
  • 41 Nuki G, Bresnihan B, Bear MB. et al . Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.  Arthritis Rheum. 2002;  46 ((11)) 2838-2846
    CrossrefPubMedGoogle Scholar
  • 42 Ostergaard M, Unkerskov J, Linde L. et al . Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.  Scand J Rheumatol. 2007;  36 ((2)) 151-154
    CrossrefPubMedGoogle Scholar
  • 43 Pierer M, Baerwald C. Biological therapy for the treatment of rheumatic diseases].  Internist (Berl). 2008;  49 ((8)) 938-946
    CrossrefPubMedGoogle Scholar
  • 44 Rubbert-Roth A, Burmester G. Recommendations on the use of rituximab for patients with rheumatoid arthritis.  Z Rheumatol. 2008;  67 ((7)) 609-613
    CrossrefPubMedGoogle Scholar
  • 45 Schiff M, Schmidely N, Lafosse C. et al . Abatacept provides an increasing magnitude of response over time in measures of rheumatoid arthritis disease activity: results from the ATTEST trial.  Ann Rheum Dis. 2008;  67 ((Suppl II)) 337 , Abstract
    PubMedGoogle Scholar
  • 46 Smolen JS, van der Heijde DM, St Clair EW. et al . Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.  Arthritis Rheum. 2006;  54 ((3)) 702-710
    CrossrefPubMedGoogle Scholar
  • 47 Solau-Gervais E, Laxenaire N, Cortet B. et al . Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.  Rheumatology (Oxford). 2006;  45 ((9)) 1121-1124
    CrossrefPubMedGoogle Scholar
  • 48 Strangfeld A, Hirse F, Listing J. et al . RA Patients Treated with Rituximab – Routine Care Data of the German Biologics Register RABBIT.  ACR Presentation. 2008;  371 , Abstract
    PubMedGoogle Scholar
  • 49 van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.  Arthritis Rheum. 2003;  48 ((6)) 1500-1503
    CrossrefPubMedGoogle Scholar
  • 50 Weinblatt ME, Keystone EC, Furst DE. et al . Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.  Arthritis Rheum. 2003;  48 ((1)) 35-45
    CrossrefPubMedGoogle Scholar
  • 51 Weinblatt ME, Kremer JM, Bankhurst AD. et al . A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.  N Engl J Med. 1999;  340 ((4)) 253-259
    CrossrefPubMedGoogle Scholar
  • 52 Wick MC, Ernestam S, Lindblad S. et al . Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.  Scand J Rheumatol. 2005;  34 ((5)) 353-358
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Prof. Dr. med. Christoph Baerwald

University Hospital Rheumatology Unit

Liebigstraße 22

04103 Leipzig

Phone: +341/972/47 10

Fax: +341/972/47 09

Email: christoph.baerwald@medizin.uni-leipzig.de

      >